{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T07:57:18Z","timestamp":1785311838681,"version":"3.55.0"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a major indication for liver transplantation (LT) and is expected to account for an increasing proportion of transplant candidates worldwide. As long-term post-transplant survival continues to improve, post-LT MASLD has increasingly emerged as a major metabolic complication affecting long-term prognosis. Unlike MASLD in the non-transplant setting, post-LT MASLD is strongly influenced by transplant-specific factors, including recipient metabolic dysfunction, immunosuppressant use, graft-related characteristics, and metabolic alterations following transplantation, resulting in substantial heterogeneity in clinical presentation and disease progression. Current evidence suggests that recipient-related metabolic factors, particularly obesity, type 2 diabetes, dyslipidemia, hypertension and post-transplant weight gain, play central roles in the pathogenesis, whereas donor-related characteristics may contribute predominantly to early liver fat accumulation. Importantly, the clinical significance of post-LT MASLD extends beyond simple steatosis and is closely associated with fibrosis progression, cardiovascular events, renal dysfunction, and other systemic metabolic complications. Nevertheless, the current literature remains highly heterogeneous. This variability likely reflects evolving disease definitions, the frequent failure to distinguish recurrent from\n                    <jats:italic>de novo<\/jats:italic>\n                    MASLD, and inconsistencies in diagnostic modalities across studies. Moreover, assessment models originally developed for MASLD in the general population may not be fully applicable to LT recipients. In this review, we comprehensively summarize the epidemiology, phenotypic heterogeneity, risk factors, pathogenesis, diagnostic and surveillance strategies, and emerging individualized management approaches for post-LT MASLD, with particular emphasis on a long-term management framework based on risk stratification. Accordingly, future management may need to focus less on steatosis alone and more on identifying patients at high risk for progressive hepatic and extrahepatic complications. A more comprehensive assessment integrating metabolic, hepatic, cardiovascular, and transplant-related factors may improve individualized surveillance and therapeutic decision-making. Advances in non-invasive imaging, multidisciplinary management, and artificial intelligence-based prediction models may further support individualized and risk-oriented care in post-LT MASLD.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1878245","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:29:46Z","timestamp":1781065786000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-transplant MASLD: a risk-stratified approach to assessment and personalized management"],"prefix":"10.3389","volume":"13","author":[{"given":"He-Yu","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun","place":["Jilin, China"]},{"name":"China-Singapore Belt and Road Joint Laboratory on Liver Disease Research, First Hospital of Jilin University, Changchun","place":["Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Qi","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun","place":["Jilin, China"]},{"name":"China-Singapore Belt and Road Joint Laboratory on Liver Disease Research, First Hospital of Jilin University, Changchun","place":["Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Yue","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun","place":["Jilin, China"]},{"name":"China-Singapore Belt and Road Joint Laboratory on Liver Disease Research, First Hospital of Jilin University, Changchun","place":["Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0352","DOI":"10.1097\/HC9.0000000000000352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013\u20132022: the dominance of metabolic dysfunction\u2013associated steatotic liver disease and alcohol-associated liver disease","volume":"8","author":"Younossi","year":"2023","journal-title":"Hepatol Commun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/tri.13358","article-title":"2018 annual report of the European Liver Transplant Registry (ELTR)-50-year evolution of liver transplantation","volume":"31","author":"Adam","year":"2018","journal-title":"Transpl Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/hep4.1915","article-title":"Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: data from the United States Scientific Registry of Transplant Recipients","volume":"6","author":"Stepanova","year":"2022","journal-title":"Hepatol Commun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/LVT.0000000000000060","article-title":"Hepatic steatosis after liver transplantation: a systematic review and meta-analysis","volume":"29","author":"Silva","year":"2023","journal-title":"Liver Transplant."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2199193","DOI":"10.1155\/2023\/2199193","article-title":"Diabetes and metabolic disorders: their impact on cardiovascular events in liver transplant patients","volume":"2023","author":"Di Cola","year":"2023","journal-title":"Can J Gastroenterol Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0168-8278(17)30343-4","article-title":"De novo non-alcoholic steatohepatitis is associated with a five-fold long-term increased mortality in liver transplant recipients","volume":"30","author":"Gitto","year":"2017","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.transproceed.2021.02.025","article-title":"Liver-related and cardiovascular outcome of patients transplanted for nonalcoholic fatty liver disease: a European single-center study","volume":"53","author":"Van Herck","year":"2021","journal-title":"Transplant Proc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/dom.70545","article-title":"Providing holistic care for patients with metabolic dysfunction-associated steatotic liver disease\/metabolic dysfunction-associated steatohepatitis: key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions","volume":"28","author":"Chen","year":"2026","journal-title":"Diabetes Obes Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.3390\/jcm13133871","article-title":"Metabolic-dysfunction-associated steatotic liver disease (MASLD) after liver transplantation: a narrative review of an emerging issue","volume":"13","author":"Savino","year":"2024","journal-title":"J Clin Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/lt.23936","article-title":"Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: Natural history based on liver biopsy analysis","volume":"20","author":"Vallin","year":"2014","journal-title":"Liver Transplant."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1097\/TP.0000000000002317","article-title":"Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation","volume":"103","author":"Narayanan","year":"2019","journal-title":"Transplantation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/TP.0000000000002485","article-title":"Management of recurrent and De Novo NAFLD\/NASH after liver transplantation","volume":"103","author":"Germani","year":"2019","journal-title":"Transplantation."},{"key":"B16","doi-asserted-by":"publisher","first-page":"E345","DOI":"10.1097\/TP.0000000000002916","article-title":"Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant: systematic review and meta-analysis","volume":"103","author":"Saeed","year":"2019","journal-title":"Transplantation."},{"key":"B17","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41574-022-00711-5","article-title":"Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver trans-plantation","volume":"18","author":"Lonardo","year":"2022","journal-title":"Nat Rev Endocrinol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e100219","DOI":"10.1136\/egastro-2025-100219","article-title":"Liver transplantations in Finland over 40 years: evolution and recent trends","volume":"3","author":"\u00c5berg","year":"2025","journal-title":"eGastroenterology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/j.jhep.2023.09.009","article-title":"Metabolic dysfunction-associated steatotic liver disease: where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?","volume":"80","author":"Choudhary","year":"2024","journal-title":"J Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.14744\/hf.2023.2023.0032","article-title":"Prevalence and predictors of metabolic-associated fatty liver disease in liver transplant recipients: a cross-sectional prospective study","volume":"4","author":"Adali","year":"2023","journal-title":"Hepatol Forum."},{"key":"B21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12876-023-02940-y","article-title":"High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver transplantation and the role of controlled attenuation parameter","volume":"23","author":"Mak","year":"2023","journal-title":"BMC Gastroenterol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"101281","DOI":"10.1016\/j.jceh.2023.09.002","article-title":"Post-transplant non-alcoholic fatty liver disease and metabolic syndrome after living donor liver transplantation in Indians","volume":"14","author":"Choudhary","year":"2024","journal-title":"J Clin Exp Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/apt.14521","article-title":"Systematic review with meta-analysis: De novo non-alcoholic fatty liver disease in liver-transplanted patients","volume":"47","author":"Losurdo","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1097\/HEP.0000000000000696","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e14965","DOI":"10.1111\/ctr.14965","article-title":"Utility and prognostic value of diagnosing MAFLD in patients undergoing liver transplantation for alcohol-related liver disease","volume":"37","author":"Vanlerberghe","year":"2023","journal-title":"Clin Transplant."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e100319","DOI":"10.1136\/egastro-2025-100319","article-title":"Metabolic dysfunction and alcohol-associated liver disease (MetALD)","volume":"3","author":"Gao","year":"2025","journal-title":"eGastroenterology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2021.101762","article-title":"Adverse effects of immunosuppression after liver transplantation","author":"Noble","year":"2021","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/biomedicines12020397","article-title":"Exploring the multifaceted landscape of MASLD: a comprehensive synthesis of recent studies, from pathophysiology to organoids and beyond","volume":"12","author":"Soto","year":"2024","journal-title":"Biomedicines."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/TP.0000000000002876","article-title":"Donor PNPLA3 and TM6SF2 variant alleles confer additive risks for graft steatosis after liver transplantation","volume":"104","author":"M\u00edkov\u00e1","year":"2020","journal-title":"Transplantation."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e00302","DOI":"10.14309\/ctg.0000000000000302","article-title":"Clinical and genetic risk factors of recurrent nonalcoholic fatty liver disease after liver transplantation","volume":"12","author":"Satapathy","year":"2021","journal-title":"Clin Transl Gastroenterol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1432-2277.2012.01576.x","article-title":"Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation","volume":"26","author":"Sprinzl","year":"2013","journal-title":"Transpl Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/lt.22004","article-title":"Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or non-alcoholic fatty liver disease","volume":"16","author":"Yalamanchili","year":"2010","journal-title":"Liver Transpl."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1097\/TP.0000000000001709","article-title":"Longterm outcomes in patients undergoing liver transplantation for nonalcoholic steatohepatitis-related cirrhosis","volume":"101","author":"Bhati","year":"2017","journal-title":"Transplantation."},{"key":"B35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/lt.25338","article-title":"Predictors of De Novo nonalcoholic fatty liver disease after liver transplantation and associated fibrosis","volume":"25","author":"Galvin","year":"2019","journal-title":"Liver Transplant."},{"key":"B36","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/MEG.0000000000001736","article-title":"De-novo nonalcoholic fatty liver disease at 5 years after liver transplantation: Prevalence and predictive factors","volume":"33","author":"Tejedor-Tejada","year":"2021","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"101704","DOI":"10.1016\/j.jhepr.2025.101704","article-title":"Steatotic liver disease and liver transplantation: candidate selection and post-transplant management","volume":"8","author":"Colmenero","year":"2026","journal-title":"JHEP Reports"},{"key":"B39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s13300-018-0374-8","article-title":"Post-liver transplantation diabetes mellitus: a review of relevance and approach to treatment","volume":"9","author":"Pel\u00e1ez-Jaramillo","year":"2018","journal-title":"Diabetes Therapy."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1291501","DOI":"10.3389\/fmed.2024.1291501","article-title":"Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies","volume":"11","author":"Habibullah","year":"2024","journal-title":"Front Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"Marchesini","year":"2016","journal-title":"J Hepatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of non-alcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Non-invasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"12489","DOI":"10.3390\/ijms232012489","article-title":"Accuracy of FIB-4 to detect elevated liver stiffness measurements in patients with non-alcoholic fatty liver disease: a cross-sectional study in referral centers","volume":"23","author":"Vigan\u00f2","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/petr.12661","article-title":"AST-to-platelet ratio index in non-invasive assessment of long-term graft fibrosis following pediatric liver transplantation","volume":"20","author":"D'Souza","year":"2016","journal-title":"Pediatr Transplant."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.transproceed.2019.01.197","article-title":"Non-invasive assessment of graft fibrosis after living donor liver transplantation: is there still a role for liver biopsy?","volume":"51","author":"El-Meteini","year":"2019","journal-title":"Transplant Proc."},{"key":"B47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ajg.2017.05.005","article-title":"APRI test and hyaluronic acid as non-invasive diagnostic tools for post HCV liver fibrosis: systematic review and meta-analysis","volume":"18","author":"El Serafy","year":"2017","journal-title":"Arab J Gastroenterol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1399-0012.2009.01152.x","article-title":"Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients","volume":"24","author":"Kamphues","year":"2010","journal-title":"Clin Transplant."},{"key":"B49","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.transproceed.2008.12.014","article-title":"APRI and FIB-4 scores are useful after liver transplantation independently of etiology","volume":"41","author":"Pissaia","year":"2009","journal-title":"Transplant Proc."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology."},{"key":"B51","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00330-010-1905-5","article-title":"The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis","volume":"21","author":"Bohte","year":"2011","journal-title":"Eur Radiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-\u22122021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J Hepatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology."},{"key":"B55","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(20)30357-5","article-title":"Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis","volume":"6","author":"Petroff","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.transproceed.2020.02.160","article-title":"The utility of assessing liver allograft fibrosis and steatosis post-liver transplantation using transient elastography with controlled attenuation parameter","volume":"53","author":"Chayanupatkul","year":"2021","journal-title":"Transplant Proc."},{"key":"B57","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.cgh.2020.03.067","article-title":"Diagnostic performance of vibration-controlled transient elastography in liver transplant recipients","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e0185192","DOI":"10.1371\/journal.pone.0185192","article-title":"Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: a meta-analysis","volume":"12","author":"Bhat","year":"2017","journal-title":"PLoS ONE."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1007\/s00330-019-06072-4","article-title":"Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"29","author":"Gu","year":"2019","journal-title":"Eur Radiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1007\/s00330-019-06071-5","article-title":"Diagnostic accuracy of hepatic proton density fat fraction measured by magnetic resonance imaging for the evaluation of liver steatosis with histology as reference standard: a meta-analysis","volume":"29","author":"Qu","year":"2019","journal-title":"Eur Radiol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/0284185115580488","article-title":"A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease","volume":"57","author":"Idilman","year":"2016","journal-title":"Acta Radiol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00330-015-3949-z","article-title":"Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis","volume":"26","author":"Singh","year":"2016","journal-title":"Eur Radiol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10334-011-0264-9","article-title":"MR spectroscopy as a tool for in vivo determination of steatosis in liver transplant recipients","volume":"24","author":"H\u00e1jek","year":"2011","journal-title":"Magn Reson Mater Phys Biol Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e70616","DOI":"10.1111\/liv.70616","article-title":"Hormone replacement therapy to tackle MASLD progression in peri-menopausal women: window of opportunity or call for precision?","volume":"46","author":"Chen","year":"2026","journal-title":"Liver Int"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e100196","DOI":"10.1136\/egastro-2025-100196","article-title":"Key takeaways from the updated multidisciplinary European MASLD guidelines","volume":"3","author":"Horn","year":"2025","journal-title":"eGastroenterology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","article-title":"EASL Clinical practice guidelines on nutrition in chronic liver disease","volume":"70","author":"Merli","year":"2019","journal-title":"J Hepatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ueg2.12525","article-title":"Therapeutic management of metabolic dysfunction associated steatotic liver disease","volume":"12","author":"Zeng","year":"2024","journal-title":"United Eur Gastroenterol J."},{"key":"B68","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jhep.2012.02.023","article-title":"Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"57","author":"Keating","year":"2012","journal-title":"J Hepatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1016\/j.transproceed.2019.03.087","article-title":"Physical condition, glycemia, liver function, and quality of life in liver transplant recipients after a 12-month supervised exercise program","volume":"51","author":"Totti","year":"2019","journal-title":"Transplant Proc."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.jhep.2022.05.005","article-title":"Associations of muscle mass and grip strength with severe NAFLD: a prospective study of 333,295 UK Biobank participants","volume":"77","author":"Chen","year":"2022","journal-title":"J Hepatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"CD007606","DOI":"10.1002\/14651858.CD007606.pub4","article-title":"Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients","volume":"2018","author":"Fairfield","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1097\/TP.0000000000001913","article-title":"Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: results of a randomized multicenter study","volume":"101","author":"Charlton","year":"2017","journal-title":"Transplantation."},{"key":"B73","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1053\/jlts.2001.24637","article-title":"Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight","volume":"7","author":"Neal","year":"2001","journal-title":"Liver Transplant."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e501","DOI":"10.1097\/TP.0000000000005361","article-title":"Impact of glucagon-like peptide-1 receptor agonists on metabolic health in liver transplant recipients","volume":"109","author":"Yakubu","year":"2025","journal-title":"Transplantation."},{"key":"B75","doi-asserted-by":"publisher","first-page":"101920","DOI":"10.1016\/j.aohep.2025.101920","article-title":"Semaglutide for the treatment of post transplantation diabetes mellitus in patients following liver transplantation is safe and effective","volume":"30","author":"Bot","year":"2025","journal-title":"Ann Hepatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/LVT.0000000000000247","article-title":"Semaglutide is effective in achieving weight loss in liver transplant recipients","volume":"30","author":"Chow","year":"2024","journal-title":"Liver Transpl."},{"key":"B77","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/LVT.0000000000000233","article-title":"Utility of glucagon-like peptide 1 receptor agonists as anti-obesity medications in liver transplant recipients","volume":"30","author":"Richardson","year":"2024","journal-title":"Liver Transpl."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1111\/ajt.12850","article-title":"Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions","volume":"14","author":"Sharif","year":"2014","journal-title":"Am J Transpl."},{"key":"B79","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.phrs.2019.01.042","article-title":"Management of diabetes mellitus in patients undergoing liver transplantation","volume":"141","author":"Grancini","year":"2019","journal-title":"Pharmacol Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1111\/j.1600-6143.2004.00613.x","article-title":"Pioglitazone in the management of diabetes mellitus after transplantation","volume":"4","author":"Luther","year":"2004","journal-title":"Am J Transplant."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1097\/01.tp.0000181165.19788.95","article-title":"Rosiglitazone therapy of posttransplant diabetes mellitus","volume":"80","author":"Villanueva","year":"2005","journal-title":"Transplantation."},{"key":"B82","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/jgh.13026","article-title":"Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"31","author":"Carbone","year":"2016","journal-title":"J Gastroenterol Hepatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.clinre.2016.11.009","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"41","author":"Dong","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites."},{"key":"B85","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s13300-020-00786-1","article-title":"A retrospective study of glucagon-like peptide 1 receptor agonists for the management of diabetes after transplantation","volume":"11","author":"Thangavelu","year":"2020","journal-title":"Diabetes Ther."},{"key":"B87","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/gutjnl-2023-330596","article-title":"Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon","volume":"73","author":"Byrne","year":"2024","journal-title":"Gut."},{"key":"B88","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1515\/mr-2024-0007","article-title":"Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease","volume":"4","author":"Chui","year":"2024","journal-title":"Medical Review."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/lt.25637","article-title":"Delayed sleeve gastrectomy following liver transplantation: a 5-year experience","volume":"25","author":"Morris","year":"2019","journal-title":"Liver Transpl."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1878245\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:29:48Z","timestamp":1781065788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1878245\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":89,"alternative-id":["10.3389\/fmed.2026.1878245"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1878245","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1878245"}}